Some Misconceptions about Understanding Autoimmunity through Experiments with Knockouts

Experimental autoimmune encephalomyelitis (EAE) has served as a prototypic model of T cell–mediated, organspecific autoimmune disease, and as a useful model for the human disease, multiple sclerosis (MS) (1). Frei et al. (2) demonstrate that in two strains of mice with a double knockout, where both TNF-α and LT-α are inactivated, that EAE may develop. The disease in these double knockout mice progresses in an apparently typical fashion, concordant with what is observed in the usual inbred strains of mice where EAE is induced: there is clinical paralysis, and histopathology reveals intense perivascular and parenchymal infiltration with CD4+ T cells and demyelination. They conclude, and I agree, that the results are surprising, given the large body of information suggesting that TNF-α and LT-α are important in the pathogenesis of EAE and MS. However, before accepting their ultimate conclusion that, “these results indicate that TNFα and LT-α are not essential for the development of EAE,” it is worthwhile to consider the limitations of the first-generation knockouts that have been employed in their study. Certain misconceptions have arisen concerning the interpretation of experiments with these contemporary knockouts. This is especially true when trying to understand the role of critical effector molecules like cytokines, in the development of complex phenotypes, like the paralysis and inflammation seen in EAE. Many of these cytokine molecules have diverse biological activities, and many of the functions of these molecules can be duplicated by other cytokines. Thus, in animals with disrupted or “knocked out” cytokine genes, one may expect many diverse changes in several physiological processes, and one might find that after all is done, that another gene and its product can replace the function of the gene that was disrupted.

[1]  K. Frei,et al.  Tumor Necrosis Factor (cid:2) and Lymphotoxin (cid:2) Are Not Required for Induction of Acute Experimental Autoimmune Encephalomyelitis , 2002 .

[2]  G. Nolan,et al.  Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis , 1997, The Journal of experimental medicine.

[3]  L. Steinman,et al.  Experimental autoimmune encephalomyelitis in IL-4-deficient mice. , 1997, International immunology.

[4]  R. W. Davis,et al.  Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Sobel,et al.  Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. , 1997, Journal of immunology.

[6]  Susumu Tonegawa,et al.  Synaptic plasticity, place cells and spatial memory: study with second generation knockouts , 1997, Trends in Neurosciences.

[7]  H. Lassmann,et al.  TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview , 1997, Journal of Neuroimmunology.

[8]  T. Owens,et al.  Interferon‐γ confers resistance to experimental allergic encephalomyelitis , 1996, European journal of immunology.

[9]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[10]  L. Steinman A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  U. Utz,et al.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein , 1996, Nature.

[12]  L. Steinman,et al.  Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). , 1996, Journal of immunology.

[13]  G. Kollias,et al.  Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Steinman,et al.  Administration of Neutralizing Antibodies to Interleukin-6 (IL-6) Reduces Experimental Autoimmune Encephalomyelitis and Is Associated with Elevated Levels of IL-6 Bioactivity in Central Nervous System and Circulation , 1995, Molecular medicine.

[15]  L. Santambrogio,et al.  Staphylococcal enterotoxin B and tumor‐necrosis factor‐α‐induced relapses of experimental allergic encephalomyelitis: Protection by transforming growth factor‐β and interleukin‐10 , 1995, European journal of immunology.

[16]  T. Olsson,et al.  Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β , 1995, Journal of Neuroimmunology.

[17]  R. Davis,et al.  Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Fontana,et al.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis , 1995, Nature Medicine.

[19]  K. Selmaj,et al.  Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I , 1995, Journal of Neuroimmunology.

[20]  C. Piccirillo,et al.  TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. , 1995, Journal of immunology.

[21]  W. Cowden,et al.  Cytokines and Murine Autoimmune Encephalomyelitis: Inhibition or Enhancement of Disease with Antibodies to Select Cytokines, or by Delivery of Exogenous Cytokines Using a Recombinant Vaccinia Virus System , 1995, Scandinavian journal of immunology.

[22]  D. Mitchell,et al.  Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production , 1994, The Journal of experimental medicine.

[23]  D. Hanley,et al.  Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains , 1994, Annals of neurology.

[24]  L. Steinman,et al.  Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen , 1993, Nature.

[25]  Y. Qin,et al.  Perforin and tumor necrosis factor alpha in the pathogenesis of experimental allergic encephalomyelitis: comparison of autoantigen induced and transferred disease in Lewis rats. , 1993, Journal of autoimmunity.

[26]  A. Cross,et al.  Anti—tumor necrosis factor therapy abrogates autoimmune demyelination , 1991, Annals of neurology.

[27]  Y. Shimamoto,et al.  Human tumor necrosis factor-α augments experimental allergic encephalomyelitis in rats , 1991, Journal of Neuroimmunology.

[28]  M. Sharief,et al.  Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis , 1991 .

[29]  D. Baker,et al.  Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis. , 1991, Cellular immunology.

[30]  E. Benveniste,et al.  Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains , 1991, The Journal of experimental medicine.

[31]  R. Clark,et al.  An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis , 1990, The Journal of experimental medicine.

[32]  Moses Rodriguez,et al.  Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor alpha. , 1990, International immunology.

[33]  D. Mitchell,et al.  Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. , 1990, International immunology.

[34]  K. Selmaj,et al.  Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro , 1988, Annals of neurology.

[35]  R. Zinkernagel,et al.  Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-α double-deficient mice , 1996 .